Patients across the UK are gaining faster access to life-changing treatments as new data shows significant improvements in clinical trial set-up times within the NHS. The latest performance indicators reveal that the average time to initiate commercial interventional clinical trials has dropped from 169 days to 122 days compared to the same period last year.

This progress is driven by a Euro 137 million government investment aimed at reforming health research processes, reducing bureaucratic delays and strengthening research infrastructure. The reforms include standardising procedures, improving regulatory timelines and expanding capacity across the clinical research ecosystem.

Health officials highlighted that faster trial set-up directly benefits patients by providing earlier access to new medicines, vaccines and therapies. Trials that previously took nearly a year to begin are now being launched within months, improving outcomes for patients with serious conditions.

Recent examples demonstrate this impact. A global study on chronic obstructive pulmonary disease (COPD) began enrolling patients in just 81 days, while a trial for advanced bowel cancer treatment was launched in 70 days, with a UK patient becoming the first in Europe to receive the therapy. Similarly, the large-scale TRANSFORM prostate cancer screening trial moved from regulatory submission to patient enrolment in under 150 days.

The UK has also recorded a growing number of global and European first patient enrolments, with 29 global and 54 European firsts reported since April 2025. This highlights the country’s increasing attractiveness as a destination for cutting-edge clinical research.

Regulatory improvements have played a key role, with most reviews now completed within 60 days and 99 percent of studies meeting approval timelines. Investments have also supported the establishment of Commercial Research Delivery Centres and enhanced funding for NHS organisations to expand trial capacity.

The government has further integrated research into the NHS planning framework, ensuring it becomes a core part of patient care. Initiatives such as the NIHR Industry Hub and the upcoming Health Research Data Service aim to streamline collaboration and improve access to patient data for research.

Industry leaders and policymakers emphasised that while the progress is significant, efforts will continue to further reduce timelines and increase patient participation in trials. The reforms are positioning the UK as one of the fastest and most efficient environments globally for clinical research, while strengthening its role in delivering innovative treatments to patients sooner.